Enhanced Severe Acute Respiratory Syndrome Coronavirus 2 Antigen–Specific Systemic Immune Responses in Multisystem Inflammatory Syndrome in Children and Reversal After Recovery

Nathella Pavan Kumar,1 Aishwarya Venkataraman,1 Arul Nancy,2 Kadar Moideen,2 Poovazhagi Varadarajan,3 Elilarseli Selluradur,3 Thankgavelu Sangaralingam,4 Ramya Selvam,4 Akshith Themmaiah,4 Suresh Natarajan,5 Ganesh Ramasamy,5 Syed Hissar,1 Umadevi Radayam Ranganathan,1 and Subash Babu6

1Department of Immunology, National Institute for Research in Tuberculosis, Indian Council of Medical Research, Chennai, India; 2ICER, National Institute for Research in Tuberculosis, National Institutes of Health–International Center for Excellence in Research, Chennai, India; 3Pediatric Intensive Care Unit, Institute of Child Health and Hospital for Children, Chennai, India; 4General Pediatrics, Dr Mehta’s Children’s Hospital, Chennai, India; and 5Pediatric Pulmonology, Rainbow Children’s Hospital, Chennai, India

Background. Multisystem inflammatory syndrome in children (MIS-C) presents with inflammation and pathology of multiple organs in the pediatric population in the weeks following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Methods. We characterized the SARS-CoV-2 antigen–specific cytokine and chemokine responses in children with MIS-C, coronavirus disease 2019 (COVID-19), and other infectious diseases.

Results. MIS-C is characterized by elevated levels of type 1 (interferon-γ, interleukin [IL] 2), type 2 (IL-4, IL-13), type 17 (IL-17), and other proinflammatory cytokines (IL-1α, IL-6, IL-12p40, IL-18, and granulocyte-macrophage colony-stimulating factor) in comparison to COVID-19 and other infectious diseases following stimulation with SARS-CoV-2–specific antigens. Similarly, upon SARS-CoV-2 antigen stimulation, CCL2, CCL3, and CXCL10 chemokines were significantly elevated in children with MIS-C in comparison to the other 2 groups. Principal component analysis based on these cytokines and chemokines could clearly distinguish MIS-C from both COVID-19 and other infections. In addition, these responses were significantly diminished and normalized 6–9 months after recovery.

Conclusions. Our data suggest that MIS-C is characterized by an enhanced production of cytokines and chemokines that may be associated with disease pathogenesis.

Keywords. MIS-C; SARS-CoV-2; COVID-19; cytokines; chemokines; pediatric population; in vitro cell culture.
them with children with COVID-19 and other infectious diseases. Our results demonstrated that children with MIS-C exhibit heightened levels of cytokines and chemokines in comparison to children with COVID-19 and other infectious diseases. In addition, in the follow-up of children with MIS-C, these cytokine and chemokine responses were normalized 6–9 months after recovery.

**METHODS**

**Ethics Statement**

Informed consent was obtained from parent/guardians of all children along with assent where appropriate. The internal ethics committees of the participating institutes approved the study.

**Study Population and Procedures**

Children of either sex, aged 12 months to 15 years, admitted to the Institute of Child Health, Dr. Mehta’s Children Hospital, Rainbow Children’s Hospital, from 1 December 2020 to 30 May 2021 with MIS-C, acute COVID-19, and other infectious diseases (dengue fever, scrub typhus fever, and Salmonella Typhi infection (enteric fever)) were included in this study (Table 1). For analyses, children were classified into 3 groups: MIS-C (n = 15), acute COVID-19 (n = 10), and other infectious diseases (n = 10). In the MIS-C group, a subset of 8 children was followed up 6–9 months after completion of treatment. Blood was collected in ethylenediaminetetraacetic acid (EDTA) tubes (BD Biosciences) and heparin tubes and processed within 4 hours of collection at the National Institute for Research in Tuberculosis, Chennai. Sampling in all children was done prior to receiving any immunomodulatory treatment. Study staff involved in immunological assays were blinded to any clinical data. Acute COVID-19 disease and severity of COVID-19 were defined according to the Indian Ministry of Health and Family Welfare guidelines [16], and children with MIS-C were diagnosed and treated according to the CDC definition for MIS-C [17, 18]. Dengue fever was confirmed by either serology or NS1 positivity. Scrub typhus was confirmed by serology (immunoglobulin M) or enzyme-linked immunosorbent assay (ELISA). Confirmed culture was used to diagnose enteric fever.

**Antigens**

The antigens SARS-CoV-2 S-RBD (spike receptor-binding domain), SARS-CoV-2 ICL (irradiated cell lysate), or *Mycobacterium tuberculosis* (Mt) WCL (whole cell lysate) (nonviral antigen control) were used as the antigenic stimuli.

**In Vitro Culture**

Whole blood cell cultures were performed to determine the levels of cytokines and chemokines. In brief, whole blood was diluted 1:1 with RPMI-1640 medium, supplemented with penicillin/streptomycin (100 U/100 mg/mL), l-glutamine (2 mM), and HEPES (10 mM) (all from Invitrogen, Carlsbad, California) and distributed in 12-well tissue culture plates (Costar). The cultures were then stimulated with SARS-CoV-2 antigens or no stimulation (media alone or baseline) in the presence of the co-stimulatory molecules anti-CD49d and anti-CD28 at 37°C for 6 hours. The supernatants were collected and assayed for IL-10, IL-6, TNF, and IFN-γ by ELISA. Samples were run with a negative control (media alone) and a positive control (SARS-CoV-2 S-RBD). The results were normalized to the baseline for each donor to account for inter-individual variability.

**Table 1. Demographic Characteristics and Hematological Parameters of the Study Population**

| Characteristic | MIS-C (n = 15) | Acute COVID-19 (n = 10) | Other Infectious Diseases (n = 10) |
|---------------|---------------|-------------------------|----------------------------------|
| Age, y, median (range) | 4.5 (1–13) | 9 (3–12) | 2 (1–13) |
| Male sex, No. (%) | 9 (60) | 7 (63.6) | 5 (50) |
| CRP <3 mg/L, No. (%) | 5 (50) | 0 (0) | 7 (46.6) |
| WBC count, 10⁶ cells/µL, GM (range) | 8.16 (3.65–13.29) | 7.27 (5.35–9.51) | 5.71 (4.41–8.19) |
| Hemoglobin, g/dL, GM (range) | 10.15 (6–16.1) | 12.17 (10.94–13.14) | 10.68 (8.3–13.09) |
| Lymphocyte, %, median (range) | 39.53 (4.85–63.95) | 44.97 (36.3–62.99) | 71.05 (12.4–80.4) |
| Neutrophils, %, median (range) | 76.50 (32–89) | 39.76 (23.28–83.3) | 26.55 (10.59–82.14) |
| Platelets (200–450) x10⁹/µL, median (range) | 267.3 (84.8–356.5) | 295.84 (151.6–433) | 264.55 (174.8–367.9) |
| Sodium (135–145 mmol/L), median (range) | 132.5 (124–137) | ... | NA |
| Ferritin, ng/mL, median (range) | 762.5 (306.1–5377) | ... | NA |
| Duration of stay, d, median (range) | 7.5 (2–13) | NA | 4 (2–6) |
| Dengue serology or NS1 positivity | ... | ... | ... |
| Scrub typhus (IgM) | ... | ... | 4 |
| Enteric fever (culture confirmed) | ... | ... | 2 |

Abbreviations: COVID-19, coronavirus disease 2019; CRP, C-reactive protein; GM, geometric mean; IgG, immunoglobulin G; IgM, immunoglobulin M; MIS-C, multisystem inflammatory syndrome in children; NA, not applicable; RT-PCR, reverse-transcription polymerase chain reaction.
for 48 hours. After 48 hours, culture supernatants were collected for estimating the cytokine and chemokine levels.

**Multiplex Assay**
The levels of cytokines and chemokines in the culture supernatants were measured using the Magpix multiplex cytokine assay system (Bio-Rad, Hercules, California). Raw cytokine/chemokine values are labeled as cytokine/chemokine values for the unstimulated condition. Net cytokine/chemokine levels are given for the stimulated condition, which indicates cytokine values following subtraction of baseline (unstimulated) values from the total stimulated values. The cytokines analyzed were interferon gamma (IFN-γ), interleukin (IL) 2, tumor necrosis factor alpha (TNF-α), IL-4, IL-5, IL-13, IL-17A, IL-1α, b, IL-6, IL-10, IL-12p70, IL-18, and granulocyte-macrophage colony-stimulating factor (GM-CSF), and chemokines analyzed were CCL1, CCL2, CCL3, CCL4, CCL11, CXCL1, CXCL2, CXCL9, CXCL10, and CXCL11, measured by ELISA using the kit from R&D Systems (Minneapolis, Minnesota).

**Statistical Analysis**
Geometric means were used for measurements of central tendency. Statistically significant differences between MIS-C, acute COVID-19, and other infectious diseases were analyzed using the Kruskal–Wallis test with Dunn multiple comparisons. P ≤ .05 was considered statistically significant and all tests were 2-sided. Wilcoxon signed-rank test was used to compare levels of culture supernatant cytokine and chemokine concentrations before and after MIS-C treatment. Analyses were performed using GraphPad Prism version 9.0 software (GraphPad, San Diego, California). RStudio was used for plotting principal component analysis (PCA) and heat maps.

**RESULTS**

**Children With MIS-C Have Elevated Type 1, Type 2, and Type 17 Cytokine Responses to SARS-CoV-2 Antigens**
To elucidate the impact of MIS-C on cytokine responses, we assessed their production by whole blood culture supernatants from children with MIS-C, COVID-19, and other infectious diseases with no stimulation or following stimulation with SARS-CoV-2 antigens. As shown in Figure 1A, children with MIS-C exhibited significantly increased production of type 1 (IFN-γ, IL-2), type 2 (IL-4 and IL-13), and type 17 (IL-17A) and other proinflammatory cytokines (IL-1a, IL-6, IL-12p70, IL-18, and GM-CSF) at baseline (no stimulation) (Figure 1B). In response to SARS-CoV-2 S-RBD and SARS-CoV-2 ICL, we observed significantly increased cytokine levels of type 1 (IFN-γ, IL-2), type 2 (IL-4 and IL-13), type 17 (IL-17A) (Figure 1A), and other proinflammatory cytokines (IL-1α, IL-6, IL-12p70, IL-18, and GM-CSF) (Figure 1B) in children with MIS-C compared to children with COVID-19 and those with other infectious diseases. In addition, upon SARS-CoV-2 S-RBD and SARS-CoV-2 ICL stimulation, we also observed elevated levels of IFN-γ, IL-2, IL-4, IL-13, and IL-17A in children with COVID-19 compared to children with other infectious diseases. In contrast, no significant differences were seen in the cytokine levels upon *Mtb* antigen stimulation (Figure 1).

**Children With MIS-C Have Elevated Chemokine Responses to SARS-CoV-2 Antigens**
To elucidate the impact of MIS-C on chemokine responses, we assessed their production by whole blood culture supernatants from children with MIS-C, COVID-19, and other infectious diseases with no stimulation or following stimulation with SARS-CoV-2 antigens. Children with MIS-C exhibited significantly increased production of CC chemokines (CCL2, CCL3, and CCL11) and CXC chemokines (CXCL1 and CXCL10) and decreased production of CXC chemokines (CXCL8) at baseline (no stimulation) (Figure 2A). In response to SARS-CoV-2 S-RBD and SARS-CoV-2 ICL, we observed significantly increased levels of CC chemokines (CCL2, CCL3, CCL4, and CCL11) and CXC chemokines (CXCL10), whereas CXCL9 alone decreased (Figure 2B) in children with MIS-C compared to those with COVID-19 or other infectious diseases. In contrast, no significant differences were seen in the chemokine levels upon *Mtb* antigen stimulation.

**Inflammatory Cytokines and Chemokines Can Strongly Distinguish Children With MIS-C From Those With COVID-19 and Other Infectious Diseases**
PCA is a statistical procedure that allows us to summarize the information content in big data analysis by means of a smaller set of “summary indices” that can be more easily visualized and analyzed. We performed PCA of IFN-γ, IL-2, IL-4, IL-17, GM-CSF, CCL2, CCL3, and CXCL10 to determine the discriminatory power of cytokines and chemokines in distinguishing children with MIS-C from COVID-19 and other infectious diseases (Figure 3). PCA evidently demonstrates the ability of these markers to differentiate MIS-C from COVID-19 and other infectious diseases, with elevated levels seen in MIS-C and COVID-19 children with no stimulation (captures 81.5% [Dim1: 68.9% + Dim2: 12.6%]) and SARS-CoV-2 S-RBD (captures 85.9% [Dim1: 78.9% + Dim2: 7%]) and SARS-CoV-2 ICL (86% [Dim1: 76.3% + Dim2: 9.7%]) antigen stimulation.

**Signature Pattern of Elevated Cytokines and Chemokines in Children With MIS-C**
Data were then z-score normalized across the entire cohort and analyzed by hierarchical clustering (Figure 4). For clustering, we used Euclidean distance measure and Ward.d2 method. Two main clusters were identified and showed good separation for MIS-C compared with other infectious diseases, with more overlap between COVID-19 subgroups. The cytokines and chemokines in different disease groups could be clustered separately with only very few misclassifications, and these signature
Children with multisystem inflammatory syndrome in children (MIS-C) have elevated type 1, type 2, type 17, and other proinflammatory cytokine responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens. Whole blood from children with MIS-C (n = 15), coronavirus disease 2019 (COVID-19) (n = 10), and other infectious diseases (Inf) (n = 10) were stimulated with medium alone, SARS-CoV-2 spike receptor-binding domain (S-RBD), SARS-CoV-2 irradiated cell lysate (ICL), and *Mycobacterium tuberculosis* whole cell lysate (*Mtb* WCL) for 12 hours. Levels of type 1, type 2, and type 17 (A) and other proinflammatory (B) cytokines were measured by multiplex assays. Each circle represents a single individual and the bars represent the geometric mean values. *P* values were calculated using the Kruskal–Wallis test with Dunn multiple comparisons. Cytokine abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon gamma; IL, interleukin; TNF-α, tumor necrosis factor.
Figure 2. Children with multisystem inflammatory syndrome in children (MIS-C) have elevated chemokine responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens. Whole blood from children with MIS-C (n = 15), coronavirus disease 2019 (COVID-19) (n = 10), and other infectious diseases (Inf) (n = 10) were stimulated with medium alone, SARS-CoV-2 spike receptor-binding domain (S-RBD), SARS-CoV-2 irradiated cell lysate (ICL), and Mycobacterium tuberculosis whole cell lysate (Mtb WCL) for 12 hours. Levels of CC (A) and CXC (B) chemokines were measured by multiplex assays. Each circle represents a single individual and the bars represent the geometric mean values. P values were calculated using the Kruskal–Wallis test with Dunn multiple comparisons.
patterns were seen with no stimulation and with SARS-CoV-2 S-RBD and SARS-CoV-2 ICL antigen stimulation.

Antigen-Specific Cytokine and Chemokine Levels Are Significantly Diminished Following Recovery

To examine whether the elevated antigen-specific culture supernatant cytokines and chemokines are directly linked with MIS-C, we measured the level of these cytokines and chemokines in MIS-C children during MIS-C and after MIS-C recovery. As shown in Figure 5A, at 6–9 months following recovery, cytokine levels of IFN-γ, IL-2, IL-13, IL-17A, IL-6, IL-1α, IL-1β, IL-18, and GM-CSF were significantly diminished compared to during MIS-C levels at both baseline (no stimulation) and as well as upon SARS-CoV-2 antigen stimulation. Similarly, as shown in Figure 5B, at 6–9 months following recovery, chemokine levels of CCL1, CCL3, CCL11, CXCL1, CXCL10, and CXCL11 were significantly diminished compared to during MIS-C levels at both baseline (no stimulation) as well as upon SARS-CoV-2 antigen stimulation.

DISCUSSION

MIS-C is a severe condition associated with COVID-19 infection. The syndrome is rare, and it remains unknown how SARS-CoV-2 infection leads to MIS-C and why it is more specific to the pediatric population. When it comes to treatment and management of MIS-C, a recent systemic review with meta-analysis of data from low- and middle-income countries (LMICs) reported that among the MIS-C–confirmed children, 63% were admitted to the pediatric intensive care unit and almost every one received intravenous immunoglobulin, 58% received corticosteroids, and 19% received alternate agents [9]. However, the exact pathogenesis of MIS-C remains vague, with virus-induced postinfective immune dysregulation appearing to play a leading role. Few other systemic review data reported that overall MIS-C prognosis is good, and reported mortality rates are 0–4% [19].

One assumption is that children with MIS-C might mount an abnormal T-cell response to the coronavirus causing inflammation. Our group previously reported on a comprehensive
plasma immune biomarker profile including a large panel of inflammatory markers comprising of cytokines, chemokines, growth factors, acute-phase proteins, and microbial translocation markers in children with MIS-C [11, 12]. A few other studies have demonstrated the immunological responses in children with either mild disease or asymptomatic infection, but antigen-specific T-cell immune responses have been rarely reported [20–22]. Similarly, very few studies till date have described and compared the antigen-specific immunological profile in MIS-C and acute COVID-19 with other infective causes. This comparison and data are crucial in LMICs and tropical countries where diseases such as dengue fever, scrub typhus, and enteric fever are endemic and present an overlapping clinical picture with MIS-C.

In our study, we found higher levels of SARS-CoV-2–specific cytokines and chemokines in culture supernatants in all children with MIS-C compared to those with COVID-19 and other infectious diseases upon antigenic stimulation. Our group has recently reported elevated baseline plasma levels of cytokine and chemokines in children with MIS-C [11]. The elevated levels of cytokines might have systemic effects and may in turn cause organ dysfunction [23]. This may possibly be the reason for children with MIS-C exhibiting multiorgan dysfunction. These findings suggest that enhancement or elevation of T-cell–specific immune responses is greater in the MIS-C and COVID-19 group than the other infectious diseases group. In addition, we have used a nonviral antigen control Mtb WCL, where we observed no statistical significant differences between the 3 study groups, indicating that reported changes seen in cytokine and chemokine levels are only SARS-CoV-2 antigen–mediated responses.

Current knowledge of MIS-C is largely inadequate, and most of the immunological findings are reported during MIS-C [10, 19], but the postrecovery (after MIS-C) manifestation...
and immune responses have not been thoroughly examined. Our current finding demonstrates that antigen-specific cytokines and chemokine levels significantly diminished after 6–9 months after recovery. This suggests that the elevated proinflammatory responses during MIS-C are normalized after recovery, indicating that immune homeostasis is achieved in these children.

Our outcomes offer some fundamental insights into the potential drivers of immune pathogenesis in MIS-C. Our study suggests that MIS-C is characterized by an enhanced immune response with increased expression of cytokines and chemokines; moreover, our longitudinal data suggest there was a diminished immune activation in the later stage of the syndrome or following recovery. Altogether, studies of antigen specificity will be important in understanding lymphocyte activation and immune dysregulation in MIS-C. Our study has limitations, as we studied a small number of children in all groups including longitudinal follow-up.

In conclusion, the findings from the current study improve our knowledge on the immunology of MIS-C and COVID-19 in children, and may benefit clinicians in the differentiating MIS-C from other common tropical conditions.

Notes

Acknowledgments. We thank the Director of the National Institute for Research in Tuberculosis (NIRT) for the constant support throughout the study; we also thank all of the pediatric consultants and infection control nurses at Kanchi Kamakoti CHILDS Trust Hospital, Institute of Child Health and Hospital for Children, Chennai, India; Dr.Mehta’s Children’s Hospital, Chennai, India; and Rainbow Children’s Hospital, Chennai, India, for their support and contributions. We also sincerely thank the NIRT International Center for Excellence in Research staff for technical support.

Financial support. This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, and the National Institute for Research in Tuberculosis–International Center for Excellence in Research.

Potential conflicts of interest. The authors declare that the research was conducted in the absence of any commercial or
financial relationships that could be construed as a potential conflict of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Rha B, Curns AT, Lively JY, et al. Respiratory syncytial virus–associated hospitalizations among young children: 2015–2016. Pediatrics 2020; 146:e20193611.
2. Shang M, Blanton L, Brammer L, Olsen SJ, Fry AM. Influenza-associated pediatric deaths in the United States, 2010–2016. Pediatrics 2018; 141:e20172918.
3. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med 2020; 383:347–58.
4. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020; 383:334–46.
5. Chiotos K, Bassiri H, Behrens EM, et al. Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series. J Pediatric Infect Dis Soc 2020; 9:393–8.
6. Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol 2020; 20:453–4.
7. Davies P, Evans C, Kanthimathinathan HK, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health 2020; 4:669–77.
8. Fernandes DM, Oliveira CR, Guerguis S, et al. Severe acute respiratory syndrome coronavirus 2 clinical syndromes and predictors of disease severity in hospitalized children and youth. J Pediatr 2021; 230:23–31.e10.
9. Sood M, Sharma S, Sood I, Sharma K, Kaushik A. Emerging evidence on multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection: a systematic review with meta-analysis. SN Compr Clin Med 2021; 3: 38–47.
10. McMurray JC, May JW, Cunningham MW, Jones OY. Multisystem inflammatory syndrome in children (MIS-C), a post-viral myocarditis and systemic vasculitis-a critical review of its pathogenesis and treatment. Front Pediatr 2020; 8:626182.
11. Venkataraman A, Kumar NP, Hanna LE, et al. Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children—a cross-sectional observational study from southern India. EBioMedicine 2021; 66:103317.
12. Kumar NP, Venkataraman A, Hanna LE, et al. Systemic inflammation and microbial translocation are characteristic features of SARS-CoV-2-related multisystem inflammatory syndrome in children. Open Forum Infect Dis 2021; 8: ofab279.
13. Consiglio CR, Cotugno N, Sardh F, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 2020; 183:968–81.e7.
14. Gruber CN, Patel RS, Trachtman R, et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell 2020; 183: 982–95.e14.
15. Carter MJ, Fish M, Jennings A, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med 2020; 26:1701–7.
16. Ministry of Health and Family Welfare (MOHFW). COVID-19 guidelines. 2021. https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021.pdf.
17. Centers for Disease Control and Prevention. Definition for multisystem inflammatory syndrome in children. 2020. https://www.cdc.gov/mis/index.html.
18. World Health Organization. Definition for multisystem inflammatory syndrome in children. 2020. https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19.
19. Malviya A, Mishra A. Childhood multisystem inflammatory syndrome: an emerging disease with prominent cardiovascular involvement-a scoping review. SN Compr Clin Med 2021; 3:48–59.
20. Jia R, Wang X, Liu P, et al. Mild cytokine elevation, moderate CD4(+) T cell response and abundant antibody production in children with COVID-19. Virol Sin 2020; 35: 734–43.
21. Moratto D, Giacomelli M, Chiarini M, et al. Immune response in children with COVID-19 is characterized by lower levels of T-cell activation than infected adults. Eur J Immunol 2020; 50:1412–4.
22. Tosif S, Neeland MR, Sutton P, et al. Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19. Nat Commun 2020; 11:5703.
23. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020; 383:2255–73.